公开(公告)号：US11207294B2

公开(公告)日：2021-12-28

申请号：US16241469

申请日：2019-01-07

申请人： CHEMOCENTRYX, INC.

发明人： James J. Campbell ,  Karen Ebsworth ,  Antoni Krasinski ,  Venkat Reddy Mali ,  Jeffrey McMahon ,  Rajinder Singh ,  Ju Yang ,  Chao Yu ,  Penglie Zhang

IPC分类号： A61K31/4035 ,  A61P17/06 ,  A61P29/00

摘要： The present disclosure provides, inter alia, methods of treating generalized pustular psoriasis (GPP) by administering an effective amount of a Chemokine Receptor 6 (CCR6) antagonist and/or a C—X—C motif chemokine receptor 2 (CXCR2) antagonist. Also provided herein are methods of modulating dysregulated IL-36 signaling in a subject in need thereof and methods of reducing neutrophil, inflammatory dendritic cell (iDC), and/or CD4 T cell accumulation in a subject in need thereof, said methods, include administering an effective amount of a Chemokine Receptor 6 (CCR6) antagonist and/or a C—X—C motif chemokine receptor 2 (CXCR2) antagonist. In some embodiments, the CCR6 and/or CXCR2 antagonist has the formula:

公开(公告)号：US11304952B2

公开(公告)日：2022-04-19

申请号：US16139745

申请日：2018-09-24

申请人： CHEMOCENTRYX, INC.

发明人： James J. Campbell ,  Zhenhua Miao ,  Thomas J. Schall ,  Israel Charo ,  Shijie Li ,  Christine Marie Janson ,  Rajinder Singh ,  Karen Ebsworth

IPC分类号： A61K31/536 ,  A61P35/00 ,  A61K31/165 ,  A61K31/357 ,  A61K45/06

摘要： The present disclosure is drawn to the combination therapy of a Chemokine Receptor 2 (CCR2) antagonist and a PD-1 and/or PD-L1 inhibitor in the treatment of cancer.

公开(公告)号：US11684606B2

公开(公告)日：2023-06-27

申请号：US17527939

申请日：2021-11-16

申请人： CHEMOCENTRYX, INC.

发明人： James J. Campbell ,  Karen Ebsworth ,  Antoni Krasinski ,  Venkat Reddy Mali ,  Jeffrey McMahon ,  Rajinder Singh ,  Ju Yang ,  Chao Yu ,  Penglie Zhang

IPC分类号： A61K31/4035 ,  A61P29/00 ,  A61P17/06

CPC分类号： A61K31/4035 ,  A61P17/06 ,  A61P29/00

摘要： The present disclosure provides, inter alia, methods of treating generalized pustular psoriasis (GPP) by administering an effective amount of a Chemokine Receptor 6 (CCR6) antagonist and/or a C-X-C motif chemokine receptor 2 (CXCR2) antagonist. Also provided herein are methods of modulating dysregulated IL-36 signaling in a subject in need thereof and methods of reducing neutrophil, inflammatory dendritic cell (iDC), and/or CD4 T cell accumulation in a subject in need thereof, said methods, include dministering an effective amount of a Chemokine Receptor 6 (CCR6) antagonist and/or a C-X-C motif chemokine receptor 2 (CXCR2) antagonist. In some embodiments, the CCR6 and/or CXCR2 antagonist has the formula:

公开(公告)号：US10532051B2

公开(公告)日：2020-01-14

申请号：US14875506

申请日：2015-10-05

申请人： ChemoCentryx, Inc.

发明人： Karen Ebsworth ,  Yu Wang ,  Yibin Zeng ,  Penglie Zhang ,  Joanne Tan

IPC分类号： A61K31/502 ,  A61K31/4412 ,  A61K31/4709 ,  A61K31/517 ,  A61K31/415 ,  A61K31/5377 ,  A61K39/395 ,  C07K16/28 ,  A61P1/00

摘要： Provided herein are compositions, methods and kits for treating inflammatory bowel disease (IBD) such as Crohn's disease and ulcerative colitis in a mammal in need thereof. The method include administering to a subject with IBD a combination therapy containing a therapeutically effective amount of a chemokine receptor 9 (CCR9) inhibitor compound and a therapeutically effective amount of an anti-α4β7 integrin antibody such as vedolizumab. Also provided herein is a kit containing the CCR9 inhibitor compound and anti-α4β7 integrin antibody.